Literature DB >> 17478593

Alexithymia, fear of bodily sensations, and somatosensory amplification in young outpatients with panic disorder.

Domenico De Berardis1, Daniela Campanella, Francesco Gambi, Raffaella La Rovere, Gianna Sepede, Laura Core, Gianferruccio Canfora, Eustachio Santilli, Alessandro Valchera, Enrico Mancini, Rosa Maria Salerno, Francesco Saverio Moschetta, Filippo Maria Ferro.   

Abstract

To elucidate the relationships between alexithymia, fear of bodily sensations, and somatosensory amplification in young patients with panic disorder (PD), authors evaluated 84 patients. Measures were the Panic Attack and Anticipatory Anxiety Scale, the Toronto Alexithymia Scale (TAS-20), the Body Sensations Questionnaire (BSQ), the Somatosensory Amplification Scale, the Agoraphobic Cognitions Questionnaire (ACQ), and the Hamilton Rating Scale for Depression. Alexithymic patients showed higher scores on all rating scales. Higher BSQ and ACQ scores, together with the Difficulty in Identifying Feelings and Difficulty in Describing Feelings subscales of the TAS-20 were predictors of severity of PD. Results of the present study do not support a direct role of somatosensory amplification in PD. Authors discuss study limitations and future research needs.

Entities:  

Mesh:

Year:  2007        PMID: 17478593     DOI: 10.1176/appi.psy.48.3.239

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  12 in total

1.  Is more emotional clarity always better? An examination of curvilinear and moderated associations between emotional clarity and internalising symptoms.

Authors:  Juhyun Park; Kristin Naragon-Gainey
Journal:  Cogn Emot       Date:  2019-05-23

2.  Impact of Alexithymia on the Lipid Profile in Major Depressed Individuals.

Authors:  Camille Point; Benjamin Wacquier; Marjorie Dosogne; Mohammed Al Faker; Hadrien Willame; Gwenolé Loas; Matthieu Hein
Journal:  J Lipids       Date:  2022-06-16

3.  Alexithymia and emotional intelligence in patients with panic disorder, generalized anxiety disorder and major depressive disorder.

Authors:  Elif Onur; Tunc Alkın; Michael J Sheridan; Thomas N Wise
Journal:  Psychiatr Q       Date:  2013-09

4.  Exteroceptive and Interoceptive Body-Self Awareness in Fibromyalgia Patients.

Authors:  Camila Valenzuela-Moguillansky; Alejandro Reyes-Reyes; María I Gaete
Journal:  Front Hum Neurosci       Date:  2017-03-13       Impact factor: 3.169

5.  Alexithymia Components Are Differentially Related to Explicit Negative Affect But Not Associated with Explicit Positive Affect or Implicit Affectivity.

Authors:  Thomas Suslow; Uta-Susan Donges
Journal:  Front Psychol       Date:  2017-10-09

6.  Somatosensory amplification, health anxiety, and alexithymia in generalized anxiety disorder.

Authors:  Vijaya Kumar; Ajit Avasthi; Sandeep Grover
Journal:  Ind Psychiatry J       Date:  2018 Jan-Jun

7.  Alexithymia mediates the relationship between interoceptive sensibility and anxiety.

Authors:  Eleanor R Palser; Clare E Palmer; Alejandro Galvez-Pol; Ricci Hannah; Aikaterini Fotopoulou; James M Kilner
Journal:  PLoS One       Date:  2018-09-13       Impact factor: 3.240

8.  Validity of the French form of the Somatosensory Amplification Scale in a Non-Clinical Sample.

Authors:  Morgiane Bridou; Colette Aguerre
Journal:  Health Psychol Res       Date:  2013-03-22

Review 9.  Alexithymia and Suicide Risk in Psychiatric Disorders: A Mini-Review.

Authors:  Domenico De Berardis; Michele Fornaro; Laura Orsolini; Alessandro Valchera; Alessandro Carano; Federica Vellante; Giampaolo Perna; Gianluca Serafini; Xenia Gonda; Maurizio Pompili; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Front Psychiatry       Date:  2017-08-14       Impact factor: 4.157

10.  The relationship between college students' alexithymia and mobile phone addiction: Testing mediation and moderation effects.

Authors:  Songli Mei; Gang Xu; Tingting Gao; Hui Ren; Jingyang Li
Journal:  BMC Psychiatry       Date:  2018-10-11       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.